Novel Approach of Vaccination against Brucella abortus 544 based on a Combination of Fusion Proteins, Human Serum Albumin and Brucella abortus Lipopolysaccharides
F. Abu Bakar
Lipopolysaccharide (LPS) of Brucella abortus is an essential component for developing the subunit vaccine against brucellosis. B. abortus LPS was extracted by n-butanol, purified by ultracentrifugation and detoxified by alkaline treatment. Pyrogenicity and toxicity of B. abortus LPS and detoxifiedLPS (D-LPS) were analyzed and compared with LPS of E. coli. Different groups of mice were immunized intraperitoneally with purified B. abortus LPS, D-LPS, a combination of LPS with human serum albumin (LPS-HSA) and B. abortus S19 bacteria; besides, control mice were inoculated with sterile saline. Two doses of vaccine were given 4 weeks apart. Mice were challenged intraperitoneally with virulent B. abortus 544 strain 4 weeks after the second dose of vaccine. Sera and spleens of mice were harvested 4 weeks after challenge. LPS-B. abortus was 10,000-fold less potent in LAL test and 100-fold less potent in eliciting fever in rabbits than in E. coli LPS. And D-LPS was very less potent in LAL test and eliciting fever in rabbits ordinary LPS. The antibody titer of anti-LPS immunoglobulin G (IgG) was higher than D-LPS. However, mice immunized with either LPS, D-LPS or LPS-HSA vaccines showed a significant protection against infection of the spleen (p<0.01). There was no significant difference between mice immunized with LPS and D-LPS in terms of protection (p<0.99). Therefore, it was concluded that D-LPS and LPS-HSA for B. abortus can be used as safer and more potent vaccines than ordinary LPS-B. abortus vaccine.
to cite this article:
I. Pakzad, A. Rezaee, M.J. Rasaee, A.Z. Hosseini, B. Tabbaraee, S. Ghafurian, A.S. Abdulamir, F. Abu Bakar and M. Raftari, 2010. Novel Approach of Vaccination against Brucella abortus 544 based on a Combination of Fusion Proteins, Human Serum Albumin and Brucella abortus Lipopolysaccharides. Journal of Biological Sciences, 10: 767-772.
Received: September 15, 2010;
Accepted: November 15, 2010;
Published: February 26, 2011
For the time being, there is no licensed vaccine against brucellosis in humans.
Several live attenuated brucella vaccines have been tried in humans, but none
was found to be satisfactory (Spink et al., 1962;
Pappagianis et al., 1966). A number of genetically
defined mutants that are attenuated for growth in macrophages or in animal models
have been developed recently, but their suitability for human use has not been
evaluated (Elzer et al., 1998; McQuiston
et al., 1999; Edmonds et al., 2002).
It has been reported that a single vaccination with a complex consisting of
Porins and smooth lipopolysaccharides from B. abortus strain 2308 provided
significant protection against challenge with the same strain and this protection
was found to be equivalent to the protection achieved by vaccination with live
attenuated strain 19 (Winter et al., 1988).
There is an evidence that mice immunized with a Brucella O-polysaccharide-bovine
serum albumin conjugate were protected against challenge with B. melitensis
strain H38 (Jacques et al., 1991). The brucella
O-polysaccharide-specific monoclonal antibodies have been shown to provide protection
against challenge with B. melitensis and B. abortus smooth strains (Cloeckaert
et al., 1992; Cloeckaert et al., 1993).
A recent report showed that mice immunized subcutaneously and intranasally with
a Brucella melitensis Lipopolysaccharide subunit vaccine were protected
against challenge with B. melitensis strain 16 M (Bhattacharjee
et al., 2006). Moreover, several Brucella proteins such as L7/L12,
Cu/Zn, superoxide dismutase, p39 have been tested as vaccines to provide protection
against brucellosis (Oliveira and Splitter, 1996; Vemulapalli
et al., 2000; Al-Mariri et al., 2001).
Besides, the anionic and amphiphilic nature of lipid A of LPS was exploited
to use LPS as conjugates with other substances for enhanced immunogenicity by
binding LPS to numerous substances such as Human Serum Albumin, which are positively
charged and possess amphipathic character (David, 1999).
Accordingly, it was conceived that binding LPS of Brucella with some Brucella immunodminant proteins might provide new approach of more effective vaccine against Brucellosis. Unfortunately, very few studies have been conducted to fulfill the newly hypothesized approach of LPS-based vaccination against Brucella infection. In order to prepare a combination of LPS with Brucella immunodominant proteins such as fusion proteins L7/L12 and P39 that are fused with human serum albumin (HAS), it was necessary to evaluate different combinations of LPS with HSA. Hence, we have developed a vaccine composed of purified LPS and detoxified LPS (D-LPS) from B. abortus S99 as well as a combination of LPS with HSA.
MATERIALS AND METHODS
Preparation of purified LPS: The LPS was extracted from killed B.
abortus 99 cells and purified by a method described previously (Goldstein
et al., 1992; Winter et al., 1996).
This latter procedure is considered a mild extraction in which the bacterial
cells are not disrupted. Briefly, 50 g of killed B. abortus organisms
were extracted in 400 mL of water-saturated n-butanol at 4°C. The aqueous
phase was obtained by using a separator funnel, centrifuged to remove insoluble
material and then pooled. To precipitated LPS, 4 volumes of methanol were added.
This precipitate was dissolved in 0.1 M Tris buffer (Merck, Germany) (pH 8)
containing 2% Sodium Dodecyle Sulfate (SDS) (Merck, Germany) and 2% mercaptoethanol
(Merck, Germany) and heated for 5 min at 100°C and for 90 min at 60°C
with proteinase K (Invitrogen, USA). After overnight incubation at 4°C,
LPS were precipitated with methanol (Merck, Germany), washed twice with cold
methanol, dissolved in water and ultracentrifuged at 100000 xg for 8 h. The
pellet was dissolved in water and freeze-dried. LPS from E.coli O157:H7
was extracted by the phenol method and purified. The protein content was estimated
by the Bradford method, with bovine serum albumin as a standard. Nucleic acid
was estimated by measuring the A260 nm. The LPS content was determined by 1,
9 dimethyl methylene blue with standard LPS in A510 nm (Apicella
et al., 1994). The SDS-PAGE was carried out by a recommended procedure
(Tsai and Frasch, 1982).
Lipopolysaccharide detoxification: The purified LPS was treated by 0.1
N NaOH (Sigma, USA) at 100°C for 2 h and pH was adjusted to 3.5 by HCl (Sigma,
USA). Upper phase was removed with great care (Poelstra
et al., 1997).
LAL and Rabbit pyrogen test: The Limulus Amebocyte Lysate (LAL) test
was performed by Gel Clot kit (Haemachem, USA) following the USP and FDA guidelines
for LAL testing. The rabbit pyrogen test was also performed as previously described
by Goldstein et al. (1992).
Vaccination and challenge of mice with B. abortus: Five groups
of female 6-8 weeks old Balb/c mice (12 mice in each group) were injected intraperitoneally
with PBS, LPS (10 μg), D-LPS (10 μg), LPS (10 μg) + HSA (5 μg),
B. abortus S19 (5x104 CFU). Injection volumes were 0.2 mL
mouse-1. A second dose was given 4 weeks after the first dose. Blood
was collected from five killed mice in each group 4 weeks after the second dose
of the vaccine. Sera were collected and stored at -20°C until they were
analyzed for antibody by an enzyme-linked immunosorbent assay (ELISA). A group
of immunized mice were challenged intraperitoneally 4 weeks after the second
dose of immunization with 5x104 CFU of virulent B. aborus
544 strain (provided by the Pasteur Institute of Iran). Spleens were aseptically
collected from killed mice 4 weeks post-challenge. The Brucella count
in term of CFU was determined by dilution and culture on Brucella agar as described
previously by Winter et al. (1996).
ELISA: The ELISA was performed in 96-well flat-bottom polystyrene microtiter
plates (Nunc, UK) using a recommended method with slight modification (Engvall
and Perlmann, 1972). Briefly, wells were coated with purified B. abortus
LPS and D-LPS at a concentration of 10 μg mL-1 in PBS-azide
(0.01 M sodium phosphate, 0.14 M sodium chloride, 0.02% sodium azide from Sigma,
USA; pH 7.5) by adding 100 μL to each well incubating the plates for 3
h at 37°C. The wells were washed three times with PBS-azide and were blocked
by adding 100 μL blocking buffer (1% casein in PBS-azide) and the plates
were incubated for 1 h at 37°C. Serial 2-fold dilutions of primary antibodies
(100 μL) were made on the plates and the plates were incubated at 37°C
for 1-3 h. Then the plates were incubated with peroxidase-conjugated rabbit
anti-mouse IgG at a concentration of 1 μg mL-1 (100 μL
per well) for 1-2 h at 37°C. The substrate used was TMB (BioRad, UK) at
a concentration of 1 mg mL-1 and incubated for 10 min at room temperature.
The action of enzyme was stopped by adding 50 μL of 20% sulfuric acid solution.
Absorbance at 450 nm was determined with an ELISA reader (Labsystems Multiskan
MCC/340; Fisher Scientific, Pittsburg, PA). The titer, expressed in Optical
Density (OD) units, was obtained by multiplying the reciprocal dilution of the
serum by the OD (A450 nm) at that dilution (Winter et
Statistical analysis: The statistical analysis performed was achieved by using statistical software SPSS version 14.2.1. Antibody titers of the studied groups of mice were expressed as means±standard deviations. The intensities of bacterial infection in spleen were expressed as mean log CFU±standard deviation per infected organ. The lower limit for the detection of infected spleen was log 2 CFU. Moreover, the differences in ELISA titers and in log CFU per infected organ were evaluated using Student's t-test. p-values less than 0.05 were considered significant.
Characterization of LPS of B. abortus: The purified LPS from
B. abortus by butanol extraction had less than 2% (w/w) contamination
of protein and less than 1% (w/w) contamination of nucleic acids. LPS was added
to 14% polyacrylamide SDS-PAGE gels containing 4 M urea (Fig.
1) stained with silver, resulting in patterns seen previously with LPS of
B. abortus (Goldstein et al., 1992).
LAL test: In the LAL assay, 1 mg of LPS- B. abortus was found
to contain 25x104 Endotoxin Units (EU), whereas 1 mg of LPS-E.
coli was found to contain 12x106 EU. The increased reactivity
of LPS-E. coli compared with that of LPS- B. abortus in the LAL
assay is probably due to its different lipid structure (Goldstein
et al., 1992). On the other hand, 10, 25, 50, 100, 200 and 400 ng
mL-1 concentrations of D-LPS were negative in the LAL test; this
showed that D-LPS-B. abortus was less toxic than LPS.
Rabbit pyrogen test: Three groups of three rabbits were inoculated with
serial dilutions of B. abortus LPS, B. abortus D-LPS, or E.
coli LPS; these groups were observed for changes in their body temperatures
every hour for 3 h. The dose of LPS that induced 50% of the maximal increase
in temperature (EC50) for LPS-B. abortus, 7x10-2 mg
mL-1, was approximately 100 fold greater than the EC50
for LPS-E. coli, 5x10-4 mg mL-1. It was indicated
that LPS-B. abortus was less pyrogenic than LPS-E.coli and was less likely
to produce endotoxic shock. On the other hand, 50, 100, 150, 200, 250, 300,
350 and 400 μg mL-1 concentrations of D-LPS in 3 mL kg-1
body weight were unable to increase the body temperature of the tested animals.
Immune response in mice: The intraperitoneal immunization of mice with B. abortus LPS, LPS-HSA and D-LPS induced antibody titers either 4 weeks after the first dose of vaccination or 4 weeks after the second dose of vaccination (p<0.05) (Table 1). Antibody titer of LPS was significantly higher than the titer of D-LPS ((p<0.05).
||SDS-PAGE of LPS of B. abortus, E. coli and Salmonella
typhimurium: samples of 10 μg (lane 1) and 20 μg (lane 4) of LPS-B.
abortus and 10 μg of LPS-E. coli (2) and S. typhimurium
(3) were used. The slower-migrating smear in lanes 1 and 4 and the slower
migrating set of bands in lanes 2 and 3 represent Intact LPS (i.e., lipid
A, Core and o-linked sugars). The fast migrant bands in all lanes represent
lipid A without O-linked sugars
|| Anti-B. abortus LPS IgG ELISA titers of mouse seraa
|aMice were immunized i.p. Two doses of vaccine
were given 4 weeks apart. Sera were collected from five of each group 4
weeks after the dose, 4 weeks after the second dose. The data are expressed
in OD units
||Log number of CFU in Spleen 4 weeks after intraperitoneally
challenge with 5x10 4 CFU of B. abortus 544a
|aMice were immunized interaperitoneally with two
doses 4 weeks apart and then challenged interaperitoneally 4 weeks after
the second dose of immunization. Bacterial CFU were determined at the indicated
times after challenge by plating organ homogenates on brucella agar. The
limit of detection was 2 CFU per organ
Interestingly, the antibody titer obtained by LPS-HSA vaccine 4 weeks after
the first dose of vaccination was five-fold higher than the titer obtained with
the LPS vaccine (p≤0.05).
Protection of mice after challenge: The protective efficacy of vaccines was measured by determining the clearance of spleens of mice against the challenge strain 4 weeks post challenge (Table 2). The protection conferred by LPS, LPS-HSA, D-LPS and S19 B. abortus strain inoculation was statistically significant and different from that obtained by PBS (p<0.007). The LPS-HSA vaccine provided significantly higher protection than that of LPS (p<0.01); however, the greatest protection provided was with the inoculation of B. abortus S19 in that significant differences between the protection obtained by S19 and that obtained by LPS, D-LPS and LPS-HSA were observed (p<0.01). However, the difference between the protection obtained by LPS and that by D-LPS was not statistically significant (p<0.995). Collectively, the results of the current study indicate that antibody titers against LPS are higher than that against D-LPS but the protection is the same.
LPS has been long seen as an ideal vaccination molecule because of its high
molecular weight and strong immunogenicity. Nevertheless, adverse effects of
LPS have been problematic; therefore, many studies have been exerted to assess
the safer and more potent modailities of LPS in vaccination. In the current
study, LPS-B. abortus, compared to LPS-E. coli in LAL and rabbit
pyrogen tests, was less potent in toxicity by 10,000 folds and less potent in
inducing fever in rabbits by about 100 folds, respectively. The toxicity of
lipid A was also changed by alkaline treatment. The difference in toxicity between
LPS-B. abortus and LPS-E. coli found in the present study is probably
due to variations in their lipid A structures. In consistence with Goldstein
study, we found that LPS-B. abortus was considerably less likely to induce
endotoxic shock than LPS-E.coli. This property of LPS-B. abortus
suggests that it might be considered as a candidate carrier for immunoconjugates
in the development of vaccines (Goldstein et al.,
1992; Pakzad et al., 2010).
The current study showed no similarity in toxicity and pyrogenicity between LPS-B. abortus and D-LPS-B. abortus. Different doses of D-LPS-B. abortus have shown that D-LPS was by far less toxic and pyrogenic, in rabbits fever and LAL tests, than ordinary LPS indicating that the D-LPS is safe and quite suitable for the use in vaccination. The decreasing antibody titer in D-LPS group compared to LPS group is probably due to decline of D-LPS immunogenicity. However, the protection test based on CFU number of target bacteria showed that both LPS and D-LPS yielded very close protection levels. This important finding indicates that difference in antibody titer can not influence the D-LPS-based protection. Moreover, this indicates that the protection gained by D-LPS or LPS was not solely attributed to the titer of the produced anti-B. abortus antibodies.
On the other hand, the highest titer response of anti-B. abortus antibodies
in LPS-HSA group reflects an essential role of the HSA component in enhancing
the potency of the currently used vaccine. These findings are consistent with
some of recent reports that confirmed that LPS and LPS-GOMP in mouse induced
decent protection against the corresponding virulent strains (Bhattacharjee
et al., 2002; Jamalan et al., 2010).
This might be explained that HSA, probably any other high molecular weight protein,
can effectively increase the immunogenicity of LPS vaccine either by increasing
the overall molecular weight of the immunogen or the combination of the two
components can lead to remodeling of the 3-dimensional conformational structure
of LPS allowing to expose more immunodominant epitopes to the immune system
of the vaccinated animal. This phenomenon needs to be studied thoroughly in
order to find the most suitable combination for LPS-based vaccines against B.
Nevertheless, the greatest protection provided in the current study was by
B. abortus S19 suggesting that the cell-mediated immunity elicited by
live vaccine induced much better protection than other forms of vaccination
used in this study. This finding is supported by the results of other reports
where live bacteria vaccines affected maximally the spleen of tested animals
in reducing properly the intensity of infection (Bhattacharjee
et al., 2002). The mechanism of the immune response against B.
abortus and vaccines protection against brucellosis have not been well described.
The complement-mediated bacterial killing (Corbeil et
al., 1988), antibody-dependent cytotoxicity by NK cells or macrophages
and phagocytosis and subsequent killing by activated macrophages (Jones
and Winter, 1992; Elzer et al., 1994) are
potential mechanisms of protection in which antibody might play a role. However,
the use of live vaccines and the use of real bacteria are hazardous when used
in human beings. Therefore, LPS products-based vaccines are still the most suitable
and accepted forms of vaccines against brucellosis.
Taken together, the current study showed that LPS and most interestingly D-LPS are potent vaccines against brucellosis. Above all, B. abortus LPS vaccines were found to be much safer than E. coli LPS vaccines. Most importantly, the D-LPS vaccine was found the safest at all and exerted no toxicity at all where it conferred the same level of protection of LPS vaccines. Therefore, it is recommended to conduct more vaccines modifications caring out to elicit antibodies and to enhance cell-mediated immune responses. This might be achieved by the addition of protein antigens in fusion protein form with HSA (gene fusion) leading to inhibition of local, as well as disseminated infections.
We are grateful to Dr. Mosaibi (Department of Immunology, Arak University of Medical Sciences, Iran). We would also like to thank Mrs. Parizad Jamshidzadeh for the edition of this manuscript.
1: Al-Mariri, A., A. Tibor, P. Mertens, X. De Bolle and P. Michel et al., 2001. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun., 69: 4816-4822.
2: Apicella, M.A., J.M. Griffiss and H. Schneider, 1994. Isolation and characterization of lipopolysaccharides, lipooligosaccharides and lipid A. Methods Enzymol., 235: 242-252.
Direct Link |
3: Bhattacharjee, A.K., M.J. Izadjoo, W.D. Zollinger, M.P. Nikolich and D.L Hoover, 2006. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infect. Immun., 74: 5820-5825.
4: Bhattacharjee, A.K., L. van de Verg, M.J. Izadjoo, L. Yuan, T.L. Hadfield, W.D. Zollinger and D.L. Hoover, 2002. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect. Immunity, 70: 3324-3329.
CrossRef | PubMed | Direct Link |
5: Cloeckaert, A., I. Jacques, P. de Wergifosse, G. Dubray and J.N. Limet, 1992. Protection against Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA and IgM monoclonal antibodies specific for a common epitope shared by the brucella A and M smooth lipopolysaccharides. Infect. Immun., 60: 312-315.
6: Cloeckaert, A., M.S. Zygmunt, G. Dubray and J.N. Limet, 1993. Characterization of O-polysaccharide specific monoclonal antibodies derived from mice infected with the rough Brucella melitensis strain B115. J. Gen. Microbiol., 139: 1551-1556.
7: Corbeil, L.B., K. Blau, T.J. Inzana, K.H. Nielsen, R.H. Jacobson, R.R. Corbeil and A.J. Winter, 1988. Killing of Brucella abortus by bovine serum. Infect. Immun., 56: 3251-3261.
8: David, S.A., 1999. The Interaction of Lipid A and Lipopolysaccharide with Human Serum Albumin. In: Endotoxins in Health and Disease, Brade, H. and S.M. Opal (Eds.). Marcel Dekker, USA., pp: 413-422.
9: Edmonds, M.D., A. Cloeckaert and P.H. Elzer, 2002. Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Vet. Microbiol., 88: 205-221.
10: Elzer, P.H., F.M. Enright, J.R. McQuiston, S.M. Boyle and G.G. Schurig, 1998. Evaluation of a rough mutant of Brucella melitensis in pregnant goats. Res. Vet. Sci., 64: 259-260.
11: Elzer, P.H., R.H. Jacobson, S.M. Jones, K.H. Nielsen, J.T. Douglas, A.J. Winter, 1994. Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: Variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology, 82: 651-658.
12: Engvall, E. and P. Perlmann, 1972. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J. Immunol., 109: 129-135.
PubMed | Direct Link |
13: Goldstein, J., T. Hoffman, C. Frasch, E.F. Lizzio and P.R. Beining et al., 1992. Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines. Infect. Immun., 60: 1385-1389.
Direct Link |
14: Jacques, I., V. Olivier-Bernardin and G. Dubray, 1991. Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate. Vaccine, 9: 896-900.
15: Jones, S.M. and A.J. Winter, 1992. Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages. Infect. Immun., 60: 3011-3014.
Direct Link |
16: McQuiston, J.R., R. Vemulapalli, T.J. Inzana, G.G. Schurig and N. Sriranganathan et al., 1999. Genetic characterization of a Tn5-disrupted glycosyltransferase gene homolog in Brucella abortus and its effect on lipopolysaccharide composition and virulence. Infect. Immun., 67: 3830-3835.
17: Oliveira, S.C. and G.A. Splitter, 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine, 14: 959-962.
18: Pappagianis, D., S.S. Elberg and D. Crouch, 1966. Immunization against brucella infections. Effects of graded doses of viable attenuated Brucella melitensis in humans. Am. J. Epidemiol., 84: 21-31.
19: Poelstra, K., W.W. Bakker, P.A. Klok, M.J. Hardonk and D.K. Meijer, 1997. A physiologic function for alkaline phosphatase: Endotoxin detoxification. Lab. Invest., 76: 319-327.
20: Spink, W.W., J.W. Hall, J. Finstad and E. Mallet, 1962. Immunization with viable Brucella organisms results of a safety test in humans. Bull. World Health Organ, 26: 409-419.
21: Tsai, C.M. and C.E. Frasch, 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Ann. Biochem., 119: 115-119.
CrossRef | Direct Link |
22: Vemulapalli, R., Y. He, S. Cravero, N. Sriranganathan, S.M. Boyle and G.G. Schurig, 2000. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect. Immunol., 68: 3286-3289.
23: Winter, A.J., G.E. Rowe, J.R. Duncan, M.J. Eis, J. Widom, B. Ganem and B. Morien, 1988. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infect. Immun., 56: 2808-2817.
24: Winter, A.J., G.G. Schurig, S.M. Boyle, N. Sriranganathan and J.S. Bevins et al., 1996. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. Am. J. Vet. Res., 57: 677-683.
25: Pakzad, I., A. Rezaee, M.J. Rasaee, A.Z. Hossieni, B. Tabbaraee and A. Kazemnejad, 2010. Protection of BALB/C mice against Brucella abortus 544 challenge by vaccination with combination of recombinant human serum albumin-l7/l12 (Brucella abortus ribosomal protein) and lipopolysaccharide. Roum. Arch. Microbiol. Immunol., 69: 5-12.
Direct Link |
26: Jamalan, M., S.K. Ardestani, M. Zeinali, N. Mosaveri and M.T. Mohammad, 2010. Effectiveness of Brucella abortus lipopolysaccharide as an adjuvant for tuberculin PPD. Biologicals, 6: 145-152.
CrossRef | PubMed | Direct Link |